Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Chronic cholestasis often results in premature death from liver failure with fibrosis; however, the molecular mechanisms contributing to biliary cirrhosis are not demonstrated. In this article, we show that the death signal mediated by TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/death receptor 5 (DR5) may be a key regulator of cholestatic liver injury. Agonistic anti-DR5 monoclonal antibody treatment triggered cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury in a mouse strain-specific manner. TRAIL- or DR5-deficient mice were relatively resistant to common bile duct ligation-induced cholestasis, and common bile duct ligation augmented DR5 expression on cholangiocytes, sensitizing mice to DR5-mediated cholangitis. Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance, reminiscent of human primary sclerosing cholangitis. Human cholangiocytes constitutively expressed DR5, and TRAIL expression and apoptosis were significantly elevated in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients. Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360 · cited 4×
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundInfluentialBid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004 · cited 1×
“The mitochondrial pathway of apoptosis appeared to play a limited role in anti-DR5 mAb-induced cholestatic liver injury, because disease onset was only partly delayed in B6 Bid / mice that are resistant to Fas-induced hepatocellular apoptosis (26) [supporting information (SI) Fig.”
BackgroundJo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775 · cited 2×
“TRAIL has been also demonstrated as a critical molecule in extrinsic tumor suppression by the immune system (3, 7, 8), and thus TRAIL is of great interest to clinical oncologists (3, 9).”
BackgroundResultSelf-citationDifferential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Research works printed but not linked: 2
- 10.1111/j.1572-0241.2002.05585.x · doi:10.1111/j.1572-0241.2002.05585.x · Paper page
- 10.1053/jhep.2001.25173a · doi:10.1053/jhep.2001.25173a
Cited by
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
“, and two recent studies have shown that the TRAIL-DR5 pathway may contribute to hepatotoxicity and bile duct toxicity in mice either treated with anti-mouse DR5 mAb or intervened by bile duct ligatio”
BackgroundSelf-citationCell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Hepatocyte Death: A Clear and Present Danger
Malhi, H., Guicciardi, M. E., & Gores, G. J. (2010) · Physiological Reviews · doi:10.1152/physrev.00061.2009 · Cited by 477
“In particular, DR5 expression is increased in the liver of bile duct-ligated mice and in liver cells exposed to toxic bile acids (106, 108, 250).”
InfluentialPathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
“Mice injected with death receptor 5 agonists have also provided insight into apoptosis in cholestatic liver disease.(98) Given the heterogeneity of PSC and the many factors that contribute to its pathogenesis, a single animal model will be challenging to develop.”
BackgroundApoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Apoptosis and Necrosis in the Liver
Guicciardi, M. E., Malhi, H., Mott, J. L., & Gores, G. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120020 · Cited by 353
“TRAIL receptor 2/ DR5 is expressed by murine cholangiocytes (333).”
Molecular mechanisms of hepatic apoptosis
Wang, K. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.499 · Cited by 329
“Another mechanism by which apoptosis occurs beyond bile acid-mediated injury includes overexpression of TNFa and its interlinking with receptors TNFR1 and TNFR2 to activate the caspase pathway in BDL mice.68 Induction of TRAIL-R2/DR5 expression and apoptosis by toxic GCDC in vitro provides new insights into the mechan…”
BackgroundThe immunobiology and pathophysiology of primary biliary cirrhosis
Hirschfield, G. M., & Gershwin, M. E. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164014 · Cited by 315
“In a possible mechanistic insight, the death signal mediated by TNFrelated apoptosis–inducing ligand (TRAIL) receptor 2/death receptor 5 may be a regulator of cholestatic liver injury, in that an agonistic anti–death receptor 5 monoclonal antibody treatment triggers cholangiocyte apoptosis, cholangitis, and cholestati…”
BackgroundPrimary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 293
“Moreover, anti-DR5 monoclonal antibody treatment in C57BL6 mice resulted in jaundice, cholangitis, and apoptosis of cholangiocytes [228].”
BackgroundPathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Hedgehog Controls Hepatic Stellate Cell Fate by Regulating Metabolism
Chen, Y., Choi, S. S., Michelotti, G. A., Chan, I. S., Swiderska-Syn, M., Karaca, G. F., Xie, G., Moylan, C. A., Garibaldi, F., Premont, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.115 · Cited by 282
Hedgehog signaling in the liver
Omenetti, A., Choi, S., Michelotti, G., & Diehl, A. M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.003 · Cited by 277
“370 Journal of Hepatology 201 its death receptors, DR4 and DR5, as major initiators of apoptosis [41,81], and the Bcl-2 family member, Mcl-1, as a key anti-apoptotic factor [49].”
BackgroundGrisendi, G., Bussolari, R., Cafarelli, L., Petak, I., Rasini, V., Veronesi, E., De Santis, G., Spano, C., Tagliazzucchi, M., Barti-Juhasz, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1865 · Cited by 245
“Moreover, anti-TRAIL-DR antibodies have a longer biological half-life than rTRAIL (21 days versus 60 minutes), potentially increasing the risk of side effects (16, 50).”
BackgroundThe Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Lleo, A., Bowlus, C. L., Yang, G.-X., Invernizzi, P., Podda, M., Van de Water, J., Ansari, A. A., Coppel, R. L., Worman, H. J., Gores, G. J., et al. (2010) · Hepatology · doi:10.1002/hep.23783 · Cited by 216
“TRAIL and FasL are pro-apoptotic ligands (28) and TRAIL can induce BEC cell damage (29).”
Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications
Roma, M. G., Toledo, F. D., Boaglio, A. C., Basiglio, C. L., Crocenzi, F. A., & Sánchez Pozzi, E. J. (2011) · Clinical Science · doi:10.1042/cs20110184 · Cited by 208
“Healthy cholangiocytes do not express TRAIL, but it is up-regulated in cholangiocytes in PBC and PSC, and this may activate the TRAIL/TRAILR-2 pro-apoptotic pathway [95].”
TRAIL receptor signaling and therapeutics
Abdulghani, J., & El‐Deiry, W. S. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.519701 · Cited by 171
“Induction of apoptosis in normal human cells, such as hepatocytes or keratinocytes, by some rTRAIL and anti-TRAIL-R mAbs in vitro has been reported [71-74] and two studies have recently shown that the TRAIL--TRAIL-R2 pathway may contribute to hepatotoxicity and bile duct toxicity in mice treated with anti-mouse TRAIL-…”
ResultMikulak, J., Bruni, E., Oriolo, F., Di Vito, C., & Mavilio, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00946 · Cited by 145
“As a matter of fact, the downstream death signal delivered by TRAIL receptor 5 is higher in PBC patients and induces cholestatic liver injury (78, 79).”
BackgroundThe Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review
Lleo, A., Leung, P. S. C., Hirschfield, G. M., & Gershwin, E. M. (2020) · Seminars in Liver Disease · doi:10.1055/s-0039-1697617 · Cited by 136
Principles of antibody-mediated TNF receptor activation
Wajant, H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.109 · Cited by 161
Is TRAIL the holy grail of cancer therapy?
Newsom-Davis, T. E., Prieske, S., & Walczak, H. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0321-2 · Cited by 151
“It has been suggested that signalling through TRAIL-R2 is responsible [162], and”
BackgroundShimoda, S., Harada, K., Niiro, H., Shirabe, K., Taketomi, A., Maehara, Y., Tsuneyama, K., Nakanuma, Y., Leung, P., Ansari, A. A., et al. (2011) · Hepatology · doi:10.1002/hep.24194 · Cited by 126
“…which is the natural receptor for TRAIL, coupled with the finding of elevated levels of TRAIL expression and apoptosis in cholangiocytes of PBC patients (26), suggests that TRAIL/Death receptor5-mediated apoptosis may be the major pathway involved in the pathogenesis of chronic cholestatic disease.”
Self-citationPrimary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management
Ilyas, S. I., Eaton, J. E., & Gores, G. J. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.035 · Cited by 122
“The proapoptotic death receptor agonist, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), has been implicated in both PSC and cancer development, presumably by this mechanism of inducing chromosomal instability.(33,34) The role of TRAIL and sublethal cell injury in the development of PSC-associated CCA…”
Functional Immune Anatomy of the Liver—As an Allograft
Demetris, A. J., Bellamy, C. O. C., Gandhi, C. R., Prost, S., Nakanuma, Y., & Stolz, D. B. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13749 · Cited by 115
“BEC apoptosis can be autocrine, paracrine and/or leucocyte-mediated (TNF-α, Fas/FasL, TNF-related apoptosis-inducing ligand (TRAIL)) (140-145), but susceptibility can be further modulated by bcl-2 family members.”
BackgroundSelf-citationLi, F., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319502110 · Cited by 110
“In contrast, FcγRIIB expression in CD11c and LysM cells, not B cells, is required for the hepatotoxic effect of agonistic αDR5 antibodies, which could be explained by the fact that residential macrophages and dendritic cells are rich and B cells are rare in liver, where DR5 on cholangiocytes is targeted (24, 25).”
BackgroundLi, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208698109 · Cited by 111
“Whereas agonistic anti-DR5 antibodies may kill tumor cells by mediating ADCC or triggering DR5 receptor-mediated apoptosis, the proapoptotic activity of MD5-1 has been proposed to be responsible for both the hepatotoxicity and tumoricidal activity of MD5-1 in the MC38 model (10, 34).”
BackgroundResultInfluentialvan der Most, R. G., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I., Prosser, A., Robinson, B. W. S., Smyth, M. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006982 · Cited by 97
“The liver toxicity that we observed in our current study seems consistent with recent work showing that the drug 5-azacytidine sensitizes hepatocytes for TRAIL apoptosis [54] and with a recent study showing that DR5-mediated apoptosis of cholangiocytes contributes to liver disease [37].”
BackgroundResultSelf-citationPrimary sclerosing cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/824168 · Cited by 93
The TNF superfamily in 2009: new pathways, new indications, and new drugs
Tansey, M. G., & Szymkowski, D. E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.002 · Cited by 103
Cell death in drug-induced liver injury
Iorga, A., & Dara, L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.01.006 · Cited by 88
Khan, H. A., Ahmad, M. Z., Khan, J. A., & Arshad, M. I. (2017) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/s1499-3872(17)60014-6 · Cited by 83
“[52] [53] [54] The TRAIL is expressed by myeloid or lymphoid immune cells in the liver like NK and NKT cells while DR5 expression is mainly found on hepatocytes.”
BackgroundNatural killer cells regulate T cell immune responses in primary biliary cirrhosis
Shimoda, S., Hisamoto, S., Harada, K., Iwasaka, S., Chong, Y., Nakamura, M., Bekki, Y., Yoshizumi, T., Shirabe, K., Ikegami, T., et al. (2015) · Hepatology · doi:10.1002/hep.28122 · Cited by 82
Self-citationThe role of natural killer cells in autoimmune liver disease: A comprehensive review
Hudspeth, K. L., Pontarini, E., Tentorio, P., Cimino, M., Donadon, M., Torzilli, G., Lugli, E., Bella, S. D., Gershwin, M. E., & Mavilio, D. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.07.003 · Cited by 82
Immunological abnormalities in patients with primary biliary cholangitis
Ma, W.-T., & Chen, D.-K. (2019) · Clinical Science · doi:10.1042/cs20181123 · Cited by 74
Chung, B. K., Karlsen, T. H., & Folseraas, T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.020 · Cited by 81
Mechanisms of tissue injury in autoimmune liver diseases
Liaskou, E., Hirschfield, G. M., & Gershwin, M. E. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0439-3 · Cited by 81
“It has been suggested that this poor cytotoxicity of NK cells may be counteracted by induction of TRAIL on activated hepatic NK cells and further cell-mediated destruction of cholangiocytes via TRAILTRAIL receptor 5, which is increased in cholangiocytes of human PSC patients [90].”
BackgroundInfluentialSchneider, B., Münkel, S., Krippner‐Heidenreich, A., Grunwald, I., Wels, W. S., Wajant, H., Pfizenmaier, K., & Gerspach, J. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.45 · Cited by 82
“Recently, it has also been shown that TRAIL-R2-mediated apoptosis might substantially contribute to chronic cholestatic disease.(35) Accordingly, an improvement of the tumor-selective action of TRAIL appears mandatory.”
BackgroundJohnson, M. (2012) · Materials and Methods · doi:10.13070/mm.en.2.113 · Cited by 92
Yan, C., Li, S., Li, Z., Peng, H., Yuan, X., Jiang, L., Zhang, Y., Fan, D., Hu, X., Yang, M., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300261e · Cited by 72
Fingas, C. D., Blechacz, B. R. A., Smoot, R. L., Guicciardi, M. E., Mott, J. L., Bronk, S. F., Werneburg, N. W., Sirica, A. E., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23729 · Cited by 66
“However, smac mimetics should be used with caution in CCA patients who additionally have primary sclerosing cholangitis because there is evidence of up-regulation of TRAIL expression in these cholestatic liver diseases.(12,54) If a smac mimetic potentiates TRAIL-mediated cytotoxicity of normal cholangiocytes in vitro,…”
BackgroundcFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
Wang, L., Jin, H., Jochems, F., Wang, S., Lieftink, C., Martinez, I. M., Conti, G. D., Edwards, F., de Oliveira, R. L., Schepers, A. G., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00462-2 · Cited by 78
Self-citationMechanisms of Disease Progression in NASH
Bohinc, B. N., & Diehl, A. M. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.002 · Cited by 69
Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Thomas, L., Dikeakos, J. D., Thomas, G., & Gores, G. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.342238 · Cited by 59
“TRAIL can also exacerbate disease processes such as cholestatic liver injury (3, 4).”
BackgroundThe pathogenesis, models and therapeutic advances of primary biliary cholangitis
Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111754 · Cited by 64
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Self-citationRavichandran, G., Neumann, K., Berkhout, L. K., Weidemann, S., Langeneckert, A. E., Schwinge, D., Poch, T., Huber, S., Schiller, B., Hess, L. U., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.023 · Cited by 56
Akram, K. M., Lomas, N. J., Forsyth, N. R., & Spiteri, M. A. (2014) · Europe PMC (PubMed Central) · Cited by 65
The liver as a central "hub" of the immune system: pathophysiological implications
Ronca, V., Gerussi, A., Collins, P., Parente, A., Oo, Y. H., & Invernizzi, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00004.2023 · Cited by 59
Role of Cholangiocytes in Primary Biliary Cirrhosis
Lleo, A., Maroni, L., Glaser, S., Alpini, G., & Marzioni, M. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1383727 · Cited by 50
Park, J.-S., Oh, Y., Park, Y. J., Park, O., Yang, H. S., Slania, S., Hummers, L. K., Shah, A. A., An, H.-T., Jang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09101-4 · Cited by 52
Stagg, J., Sharkey, J., Pommey, S., Young, R., Takeda, K., Yagita, H., Johnstone, R. W., & Smyth, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806849105 · Cited by 48
“Although we did not observe any toxicity of the single or combination mAbs in our study and MD5-1 can be administered safely to BALB/c mice at very high doses (26, 32), cholangiocyte toxicity and bile duct occlusion is observed in C57BL/6 mice treated with high doses of MD5-1, and hepatotoxicity with increased serum a…”
BackgroundSelf-citationShivange, G., Urbanek, K., Przanowski, P., Perry, J. S. A., Jones, J., Haggart, R., Kostka, C., Patki, T., Stelow, E. B., Petrova, Y. I., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.005 · Cited by 49
“The observed elevated AST/ALT levels and lobular hepatitis inMD5-1-treated animal are in agreement with previous reported MD5-1 hepatotoxicity in C57BL/6 mice (Takeda et al., 2008).”
InfluentialImmune system and cholangiocytes: A puzzling affair in primary biliary cholangitis
Ronca, V., Mancuso, C., Milani, C., Carbone, M., Oo, Y. H., & Invernizzi, P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0320-200r · Cited by 46
Pathobiology of biliary epithelia
Cheung, A., Pisarello, M. J. L., & LaRusso, N. F. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.024 · Cited by 50
The immunopathology of human biliary cell epithelium
Chuang, Y., Lan, R. Y., & Gershwin, M. E. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0172-5 · Cited by 43
“Although absent in normal conditions, the expression of TRAIL by diseased cholangiocytes in PBC and PSC may be an attempt by cholangiocytes to control the inflammatory responses in these diseases by targeting DR-expressing leukocytes [30].”
BackgroundInvolvement of cholangiocyte proliferation in biliary fibrosis
Priester, S., Wise, C., & Glaser, S. S. (2010) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v1.i2.30 · Cited by 41
Comparison of Interleukin-17- Producing Cells in Different Clinical Types of Alopecia Areata
Tojo, G.-I., Fujimura, T., Kawano, M., Ogasawara, K., Kambayashi, Y., Furudate, S., Mizuashi, M., & Aiba, S. (2013) · Dermatology · doi:10.1159/000353159 · Cited by 40
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
Cadamuro, M., Brivio, S., Spirlì, C., Joplin, R., Strazzabosco, M., & Fabris, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010149 · Cited by 43
“A defective function of Fas and DR4/DR5 represents an additional mechanism of tumor chemoresistance.”
BackgroundInfluentialAzad, A. I., Krishnan, A., Troop, L., Li, Y., Katsumi, T., Pavelko, K., Kostallari, E., Guicciardi, M. E., & Gores, G. J. (2020) · Hepatology · doi:10.1002/hep.31211 · Cited by 39
Zhao, Y., Wei, S., Chen, L., Zhou, X., & Ma, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164202 · Cited by 45
“Interest ingly, in a similar inflammatory environment, compared with other chronic cholestatic liver diseases, the expression of WAF1 and p53 in the BECs in patients with PBC is more significant, which is related to bile duct epithelial cell apoptosis (93) Figure 2.”
BackgroundKawata, K., Kobayashi, Y., Gershwin, M. E., & Bowlus, C. L. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8324-0 · Cited by 40
“Death receptor 5 (DR5) is constitutively expressed by BECs in normal conditions and is significantly upregulated in BECs of some biliary diseases, which may result in their apoptosis via ligation by TRAIL expressed by activated cytotoxic lymphocytes [46].”
BackgroundInfluentialGlaser, S. S., Onori, P., Wise, C., Yang, F., Marzioni, M., Alvaro, D., Franchitto, A., Mancinelli, R., Alpini, G. D., Munshi, M. K., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.008 · Cited by 41
Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., Zhang, H., He, Y., Lu, B., Jin, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12097-6 · Cited by 46
Arshad, M. I., Piquet‐Pellorce, C., Filliol, A. A., L’Helgoualc’h, A., Lucas‐Clerc, C., Jouan-Lanhouet, S., Dimanche‐Boitrel, M., & Samson, M. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1270-6 · Cited by 39
Zhao, S., Li, W., Fu, N., Zhou, G., Liu, S., Jiang, L., Zhang, Y., Wang, R., Nan, Y., & Zhao, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14752 · Cited by 34
Song, G., Weng, F., Zou, B., Zhao, J., Jin, J., Yan, D., Huang, K., Sun, X., Liu, C., Hu, Y., et al. (2023) · Clinical Science · doi:10.1042/cs20220674 · Cited by 32
Guicciardi, M. E., Werneburg, N. W., Bronk, S. F., Franke, A. A., Yagita∥, H., Thomas, G., & Gores, G. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092124 · Cited by 34
“In an experimental model employing a mouse DR5-specific antibody (MD5-1) capable of inducing liver damage [40], Pacs-2 mice displayed significantly less apoptosis and liver damage compared to C57BL/6 wild-type mice as assessed by TUNEL assay and serum transaminase levels, respectively (Fig.”
MethodSelf-citationPrimary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes
Lleò, A., Shimoda, S., Ishibashi, H., & Gershwin, M. E. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0303-8 · Cited by 32
“Indeed, BECs participate in immune responses, protecting against pathogens by expressing TLR and antimicrobial peptides [84]; act as antigen-presenting cells (APCs) by expressing human leukocyte antigen molecules and co-stimulatory molecules [66, 85, 86]; recruit leukocytes to the target site by expressing adhesion mo…”
BackgroundHow the biliary tree maintains immune tolerance?
Zhang, H., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.019 · Cited by 37
He, K., Pan, X., Zhou, H.-R., & Pestka, J. J. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs266 · Cited by 33
“control and calculated by relative quantification (∆∆Ct) (Takeda et al., 2008).”
MethodDrug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics
Bessone, F., Hernández, N., Tanno, M., & Roma, M. G. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1729972 · Cited by 35
Ozeki, J., Uno, S., Ogura, M., Choi, M., Maeda, T., Sakurai, K., Matsuo, S., Amano, S., Nebert, D. W., & Makishima, M. (2010) · Toxicology · doi:10.1016/j.tox.2010.11.003 · Cited by 32
“The TNF-related apoptosis-inducing ligand TNFSF10 (TRAIL) and its receptor, death receptor-5 TNFRSF10B (DR5; TRAIL receptor 2), have been shown to contribute to liver injury by BDL (Takeda et al., 2008).”
BackgroundMitchell, C., Mahrouf‐Yorgov, M., Mayeuf-Louchart, A., Robin, M., Mansouri, A., Fromenty, B., & Gilgenkrantz, H. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.163 · Cited by 28
Apotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario
Lleò, A., & Invernizzi, P. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.01.005 · Cited by 28
Fernández-Álvarez, S., Juan, V. G., Zubiete‐Franco, I., Barbier‐Torres, L., Lahoz, A., Parés, A. R., Luka, Z., Wagner, C., Lu, S. C.-L., Mato, J. M., et al. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.151 · Cited by 31
Pathophysiology of primary biliary cholangitis
Gulamhusein, A. F., & Hirschfield, G. M. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.05.012 · Cited by 35
“This apotope is recognized by circulating AMAs and the resultant antigen-antibody complex subsequently stimulates the immune system resulting in widespread immune activation leading to apoptosis of neighbouring cells(43).”
BackgroundCholestasis and cholestatic syndromes
Hirschfield, G. M., & Heathcote, E. J. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32832914b4 · Cited by 27
Nalapareddy, P. D., Schüngel, S., Hong, J., Manns, M. P., Jaeschke, H., & Vogel, A. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090304 · Cited by 26
“study revealed that tumor necrosis factor-related apoptosis-inducing ligand/DR-5 mediated apoptosis of cholangiocytes is an important determinant in BDL induced liver injury, which induces an inflammatory response within the liver and subsequently hepatocyte oncosis.(18) The mitochondrial pathway of apoptosis plays on…”
BackgroundHellen, D. J., Bennett, A. L., Malla, S. R., Klindt, C., Rao, A., Dawson, P. A., & Karpen, S. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000029 · Cited by 25
“Thirty-week-old female Fl/Fl and LKO mice bile ducts were isolated with minor modifications as reported.[31,32] Statistical analysis”
MethodImmunologic Responses and the Pathophysiology of Primary Biliary Cholangitis
Chen, R., Tang, R., Ma, X., & Gershwin, M. E. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.003 · Cited by 28
Chen, B., Ning, J., Gu, J. T., Cui, J. G., Yang, Y., Wang, Z., Zeng, J., Yi, B., & Lu, K. Z. (2014) · Liver International · doi:10.1111/liv.12655 · Cited by 24
“Apoptosis is one of the most important forms of injury, including that induced by CBDL (20, 21), and caspase-3 plays a central role in the apoptosis of many cell types (22, 23).”
The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma
Cadamuro, M., Al-Taee, A., & Gonda, T. A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.027 · Cited by 28
Mondal, T., Gaur, H., Wamba, B. E. N., Michalak, A. G., Stout, C., Watson, M. R., Aleixo, S. L., Singh, A. N., Condello, S., Faller, R., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01229-7 · Cited by 23
“To test the negative regulation of TCR signaling by FasL, T cells were serum starved overnight in a complete medium supplemented with 0.5% FCS.”
MethodInfluentialFinnberg, N. K., Gokare, P. R., Navaraj, A., Kuhs, K. A. L., Cerniglia, G. J., Yagita∥, H., Takeda, K., Motoyama, N., & El‐Deiry, W. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2759 · Cited by 24
“DR5-dependent liver toxicity occurs following high-dose treatment with MD5-1 Previously reported data have shown that liver toxicity may arise in mice following higher doses of MD5-1 than applied here (9).”
InfluentialSelf-citationNK Cell Subtypes as Regulators of Autoimmune Liver Disease
Jiao, G., & Wang, B. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/6903496 · Cited by 25
“A TRAIL-dependent mechanism is crucial for the NK cell-mediated lysis of biliary epithelial cells and results in cholestatic liver injury [46, 47].”
BackgroundKrishnan, A., Katsumi, T., Guicciardi, M. E., Azad, A. I., Öztürk, N. B., Trussoni, C. E., & Gores, G. J. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.02.013 · Cited by 21
Salas‐Silva, S., Nieves, A. S., López-Ramirez, J., Bucio, L., Gómez-Quiroz, L. E., Gutiérrez‐Ruíz, M. C., & Roma, M. G. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.044 · Cited by 22
Mondal, T., Shivange, G., Tihagam, R. D., Lyerly, E., Battista, M., Talwar, D., Mosavian, R., Urbanek, K., Rashid, N. S., Harrell, J. C., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012716 · Cited by 20
“…lexatumumab (Marini, 2006), apomab (Camidge, 2008), AMG655 (Graves et al, 2014), and tigatuzumab (Forero-Torres et al, 2015), have been tested clinically after proven effective in various immunodeficient xenograft solid tumor models (Camidge, 2008; Kaplan-Lefko et al, 2010; Tamada et al, 2015).”
BackgroundWhy Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
Molinaro, A., & Marschall, H. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0345-y · Cited by 19
Calcium Signaling in Cholangiocytes: Methods, Mechanisms, and Effects
Rodrigues, M. Â., Gomes, D. A., & Nathanson, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123913 · Cited by 20
Kellerer, M., Javed, S., Casar, C., Will, N., Berkhout, L. K., Schwinge, D., Krebs, C. F., Schramm, C., Neumann, K., & Tiegs, G. (2024) · Hepatology · doi:10.1097/hep.0000000000000830 · Cited by 17
“[18] However, we demonstrated enhanced cholangiocyte apoptosis in the absence of TRAIL, probably due to increased lymphocyte cytotoxicity.”
BackgroundGuicciardi, M. E., Krishnan, A., Bronk, S. F., Hirsova, P., Griffith, T. S., & Gores, G. J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.459 · Cited by 17
“Moreover, the TRAIL/TRAIL-receptor system has been previously implicated in the development of acute sclerosing cholangitis in mice, although the study was mostly based on data obtained following systemic injection of a TRAIL receptor agonistic antibody and did not fully examine the role of endogenous TRAIL.(5) Theref…”
BackgroundMethodInfluentialGehrke, N., Nagel, M., Straub, B. K., Wörns, M., Schuchmann, M., Galle, P. R., & Schattenberg, J. M. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00097.2017 · Cited by 17
“Apoptotic cell death results from activation and increased expression of cell death receptor molecules, oxidative stress, and MAPK signaling pathways, in particular, JNK (23, 52, 53).”
Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments
Trivedi, P. J., & Cullen, S. (2012) · Hepatology International · doi:10.1007/s12072-012-9362-7 · Cited by 19
“Interactions between apotopes, macrophages, and serum lead to a powerful production of cytokines such as TNFa, which exacerbates apoptosis of neighboring cells [77, 79].”
BackgroundCutting-Edge Issues in Primary Biliary Cirrhosis
Folci, M., Meda, F., Gershwin, M. E., & Selmi, C. F. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8253-3 · Cited by 16
“Data sustaining the role of BECs in pathogenesis of PBC are related to the presence of AMA-accessible PDC-E2 within BEC apoptotic bodies [159] (Fig.”
BackgroundInfluentialZen, Y., Hübscher, S. G., & Nakanuma, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00009-1 · Cited by 21
Self-citationEtiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity
Maretti-Mira, A. C., Salomon, M. P., Hsu, A. M., Dara, L., & Golden‐Mason, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1137034 · Cited by 19
“Human cholangiocytes constitutively expressed DR5 (TRAIL receptor), and the importance of TRAIL/DR5 signaling for the progression of cholestatic liver injury has been already shown (64).”
BackgroundGut Microbiome and Bile Acid Interactions
Wu, N., Bayatpour, S., Hylemon, P. B., Aseem, S. O., Brindley, P. J., & Zhou, H. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.11.004 · Cited by 17
Metadata
- Authors
- Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., Cretney, E., Yagita, H., Sueyoshi, N., Sato, N., Nakanuma, Y., Smyth, M. J., & Okumura, K.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Trung tâm Nghiên cứu Y sinh (VN)
- Juntendo University (JP)
- Kanazawa University (JP)
- University of Bern (CH)
- *Department of Immunology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-05
- Volume
- 105
- Issue
- 31
- Pages
- 10895-10900
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2504811
- OpenAlex
- W2171653534
- Semantic Scholar
- 808def9695bd321dc3e05100e71a911d21259847
- Cited by
- 148
- References
- 45
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 12 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 11 · 2018: 3 · 2017: 13 · 2016: 2 · 2015: 6 · 2014: 10 · 2013: 14 · 2012: 11
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- DR5, TRAIL receptor 2, apoptosis, cholestatic liver disease, primary sclerosing cholangitis, primary biliary cirrhosis, cholangiocytes, cholangitis, common bile duct ligation, liver fibrosis, TRAIL
- MeSH terms
- Animals, Antibodies, Monoclonal, Cholangitis, Cholestasis, Flow Cytometry, Humans, Immunohistochemistry, Mice, Mutant Strains, Apoptosis, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.